We have previously demonstrated that the expression of FGFR3 is frequently downregulated in colorectal carcinoma cells. Here The fibroblast growth factor receptor (FGFR) is a transmembrane tyrosine kinase receptor responsible for mediating cellular responses to FGFs signaling (Ornitz, 2000) . Currently, four members of the FGFR family (FGFR1-4) have been identified, which are composed of an extracellular Ig-like domain, transmembrane domain, and intracellular kinase domain (McKeehan et al., 1998; Ornitz and Itoh, 2001 ). They regulate a multitude of cellular processes, including cell growth, differentiation, migration and survival, and have been implicated in pathological processes including angiogenesis, wound healing, and tumorigenesis (Basilico and Moscatelli, 1992; Shaoul et al., 1995; Werner, 1998; Kornmann et al., 2002) . These receptors are widely expressed in many tissues and different cell types, and the temporal control of their expression is an important mechanism for regulating physiologically relevant signals (Johnson and Williams, 1993; Cancilla et al., 1999) . It is now evident that the inappropriate expression of FGFRs can contribute to malignant progression (Yamaguchi et al., 1994) .
The fibroblast growth factor receptor (FGFR) is a transmembrane tyrosine kinase receptor responsible for mediating cellular responses to FGFs signaling (Ornitz, 2000) . Currently, four members of the FGFR family (FGFR1-4) have been identified, which are composed of an extracellular Ig-like domain, transmembrane domain, and intracellular kinase domain (McKeehan et al., 1998; Ornitz and Itoh, 2001 ). They regulate a multitude of cellular processes, including cell growth, differentiation, migration and survival, and have been implicated in pathological processes including angiogenesis, wound healing, and tumorigenesis (Basilico and Moscatelli, 1992; Shaoul et al., 1995; Werner, 1998; Kornmann et al., 2002) . These receptors are widely expressed in many tissues and different cell types, and the temporal control of their expression is an important mechanism for regulating physiologically relevant signals (Johnson and Williams, 1993; Cancilla et al., 1999) . It is now evident that the inappropriate expression of FGFRs can contribute to malignant progression (Yamaguchi et al., 1994) .
Transcriptional silencing of genes in eukaryotic cells is a primary mechanism that contributes to the maintenance of committed gene expression patterns (Gasser and Cockell, 2001; Moazed, 2001) . Evidence from a number of studies suggests that FGFRs are involved in several and sometimes opposing functions requiring tight regulation of their expression (Chesi et al., 1997; Feng et al., 1997; Jang et al., 2000) . In our previous observations, we detected a frequent silencing of FGFR3 in primary colorectal tumors (Jang et al., 2000) . Here, we report that FGFR1 is overexpressed in colorectal carcinoma cells. We also report that the gene expressions between FGFR1 and FGFR3 are mutually exclusive in human colorectal carcinoma cell lines and the disruption of FGFR1 expression by introducing of FGFR1 small interfering RNA (siRNA) is effective in elevating FGFR3 expression and tumor suppressive activities. These observations suggest that reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal tissue plays an important role in the progression of the carcinomas to malignancy.
FGFRs expression was characterized in human colorectal carcinoma cell lines by RT-PCR Southern blot analysis to determine the inter-receptor relationship in gene expression among the FGFRs. As shown in Figure 1a , we observed a reciprocal relationship in gene expression between the FGFR1 (IIIc) and FGFR3 (IIIb), except for SW403 and no differences in FGFR2 and FGFR4. These findings strongly suggest a reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal carcinoma cells.
On the basis of these findings, the reciprocal relationship in gene expression between FGFR1 and FGFR3 was evaluated using siRNA to knock down FGFR1 expression in HCT-116 cells, which endogenously express FGFR1, but not which endogenously express FGFR1, but not FGFR3. HCT116 cells were transfected with a 21-nucleotide FGFR1 siRNA, and the expression level of FGFR3 was examined. As shown in Figure 1b and c, we observed a clear increase of FGFR3 expression with the decrease of endogenous FGFR1 expression over time after transfection. In contrast, no increase of FGFR3 was observed for control siRNA. Similar results were obtained for DLD-1, HCT8 and Colo320 cells, which endogenously express FGFR1, but not FGFR3 (data not shown). To further confirm this observation, we knock down FGFR3 expression in SW480 cells, which endogenously express FGFR3, but not FGFR1 and analysed the induction of FGFR1 expression. As expected, we observed a clear induction of FGFR1 with the decrease of endogenous FGFR3 expression after transfection (Figure 1d ). These results strongly suggest that the decrease of FGFR1 expression disrupt the silencing of FGFR3, resulting in the induction of FGFR3 expression, presumably because of the reciprocal silencing mechanism between FGFR1 and FGFR3.
We have previously observed the silencing of FGFR3 in 13 of 36 primary colorectal tumors (Jang et al., 2000) . The reciprocal silencing between FGFR1 and FGFR3 predicts an increase in FGFR1 transcripts in the corresponding tumors. Indeed, we found the strong increase of FGFR1 transcripts in all 13 cases (Figure 2) . Overall, 27 of the 36 primary tumors (75%) showed an increase in FGFR1 transcripts in tumor samples, whereas 25 of the 36 primary tumors (69%) showed decrease in FGFR3 transcripts in tumor samples (Table 1) . Thus, FGFR3 is expressed ubiquitously in normal colorectal epithelial cells, but its expression is commonly decreased in colorectal carcinoma cells, while FGFR1 is increased in colorectal carcinoma cells during malignant progression in carcinoma.
To evaluate the effect of induction of FGFR3 by the decrease of FGFR1 on cell growth properties, we compared the cellular proliferation rates and in vitro clonigenicity. FGFR1 siRNA-treated HCT116 cells proliferated more slowly than nontreated HCT116 cells (control) or control siRNA-treated HCT116 cells (Figure 3a ). FGFR3-transfected HCT116 cells were also severely impaired in their clonigenicity in vitro, when compared with vector-transfected HCT116 cells (control), which formed colonies in soft agar with high efficiency (Figure 3b ). The first-strand cDNA was synthesized from 1 mg of total RNA using the SuperScript II preamplification system (Invitrogen). As a control for mRNA loading, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was amplified. RT-PCR amplified products were electrophoretically separated on 1.5% agarose gels and transferred onto Hybond-N membranes (Amersham-Pharmacia). Membranes were hybridized at 501C using [g 32 P]ATP 5 0 -end-labeled hybridization cDNA probes under stringent conditions and membranes were washed with 0.1% SSC and 0.1% SDS at 561C. Subsequently, membranes were exposed to X-ray films for 24 h. The following sense and antisense primers were used (GenBankt accession numbers are in parentheses): FGFR1 (M34641), nucleotides 1526 -1546 and 1956 -1936 FGFR2 (M80634) , nucleotides 1666-1686 and 2128-2108; FGFR3 (BX537709), nucleotides 1502 -1522 and 1964 -1944 FGFR4 (L03840) FGFR3 has been shown to transduce a different signal that either inhibits or stimulates cell proliferation depending on the cell type (Chesi et al., 1997; Richelda et al., 1997; Dailey et al., 2003) . The phenotype observed in transgenic and knockout mouse suggests that the dysregulation of FGFR3 could impair cell growth and differentiation Deng et al., 1996) . Indeed, FGFR3 expression has been associated with differentiation in Caco-2 intestinal epithelial cells (Kanai et al., 1997) , suggesting that FGFR3 may maintain the differentiated state in colorectal tissue. In support of this, a recent study demonstrated that, in the normal postnatal brain, the spatial and temporal expression pattern of FGFR3 parallels the appearance of differentiated oligodendrocytes (Oh et al., 2003) . Thus, FGFR3 may play a role different from the other FGFR family members, particularly FGFR1, which is overexpressed in many tumor types (Luqmani et al., 1992; Jacquemier et al., 1994; Yamaguchi et al., 1994; Giri et al., 1999) .
Our previous studies showed that the expression of FGFR3 is frequently downregulated in colorectal carcinoma cells (Jang et al., 2000) . We now demonstrated that FGFR1 is overexpressed in colorectal carcinoma cells and the gene expressions between FGFR1 and FGFR3 are mutually exclusive. These results suggest that the reciprocal regulation of FGFR1 and FGFR3 transcripts in colorectal carcinoma cells is reminiscent of their complementary expression pattern in colorectal tumorigenesis. Therefore, FGFR1 may confer a selectable advantage on clones of cells in colorectal tumorigenesis, favoring proliferation, whereas FGFR3 may have the effect of an unfavorable negative regulation of progression of the carcinomas to malignancy, probably promoting differentiation. In support, several studies using BaF3 cells system have indicated that FGFR1 is much better at producing mitogenic signals than FGFR3 (Chellaiah et al., 1994; Wang et al., 1994; Ornitz et al., 1996) .
The variety of FGFR family receptors is increased by mutually exclusive alternative splicing in the COOHterminal half of Ig-like-III domain, resulting in either the IIIb or IIIc isoform of the FGFR, which provide further diversity and ligand specificity (Stauber et al., 2000) . This alternative splicing event is regulated in a tissue-specific manner (Shi et al., 1994) . The IIIb exon appears to be expressed in epithelial tissues while the IIIc exon is expressed in mesenchymal tissues. Our observation of the increase of mesenchymal cell receptor FGFR1IIIc isoform at the expense of resident epithelial cell receptor FGFR3IIIb isoform in colorectal carcinoma cells supports that the disturbances of mesenchymalepithelial interaction play important role in tumor progression.
In summary, we have demonstrated that the gene expression of FGFR1 and FGFR3 in colorectal carcinoma cells is in reciprocal relationship. We have also shown that the disruption of FGFR1 expression by introducing of FGFR1 siRNA was effective in elevating FGFR3 expression and tumor suppressive activities. However, molecular details involved in such a switch are largely unknown. Nevertheless, to our knowledge, the reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal tissue plays an important role in the progression of the carcinomas to malignancy.
